Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open; thin trading?

July 3, 2018 7:23am

Mid-week holiday’s don’t set expectation but, do exasperate anticipation of what’s sustainable

Pre-open indications: 4 SELLs

RMi reports the pricing component of pre-open indications that shed light on share pricing events and its follow-on value!

Want to know WHY, subscribe!

U.S. stock index futures indicated a firmer session

Dow futures are UP +0.42% (+101 points) and NASDAQ futures are UP +0.49% (+35 points)

US futures point to a higher open amid elevated trade war anxiety

European markets edge higher after Germany’s Merkel strikes migration deal

Asian shares closed mixed after stumbling amid trade tensions

Data docket: factory orders for May are expected to be published at around 10 a.m. ET, with light vehicle sales data for June set to follow later in the session.

Henry’omics:

I am worried about whether empty investor and trading “seats’, low volumes and how a mid-week holiday extends a long weekend and the effect on pricing as speculation is rampart! The moves in pre-market trade also come shortly before initial U.S. and Chinese tariffs are due to take effect.

It’s that time again, quarterly results are being prepared: loss per share (LPS), operational spending, ATM usage and the always lingering issues of stock-based compensation.

A new metric to watch for is CEO, new management additions and BOD transition costs as well as their costs of replacement – MDXG (the mass resignations) and BSTG (loss of on-third or two directors of their BOD) come to mind; let’s not forget restructuring costs in some cases.

Today’s indications:

The iShares Nasdaq Biotechnology (IBB) is indicating an upside of +0.13% in Tuesday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is indicating an upside of +0.32% in Tuesday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Tuesday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a downside -0.14% in Tuesday’s pre-open

I always want to know what happened PRIOR to what might happen today – it sets a tone of consequence!

From Monday’s night’s newsletter: “Q3 starts with a boom and a broom with a new month, quarter and new “rules” for investment – guidance, transparency and delivering on “promises”. The problem in the sector is that the “operational” truths have its “variants” as seen by some management(s)! The magnifying lens will be more in focus!

Reiterating, “The KEY for Q3 will be news as the summer months will reduce “eyes” on the sector other than SPECULATION!”

The iShares NASDAQ Biotechnology (IBB) was up +0.79% after Friday’s +1.73%, Thursday’s +0.57%, Wednesday’s -2.04% and last Tuesday’s -0.43% … with a negative aggregate of -1% - look for some upside in the second trading day of July.

Of the 45 companies covered on Monday; 15 downside equities finished in a range of -$0.10 (AXGN) to -$2.46 (MDXG) while the 27 upside equities oscillated from +$0.10 to $3.58 with 3 flat close.

Monday’s decliners ranged from -0.20% <AXGN -$0.10> to -38.5% <MDXG -$2.46> in 15 equities;

Monday’s gainers ranged from +0.04% <AST +$0.00> to +31.38% <BLFS +$3.58 > in 27 equities;

Companies in my headlights – It’s your decision; I provide the idea and context:

UniQure N.V. (QURE) closed up +$1.38 to $39.19 with low volume of 193.8 K shares traded <3 month average = 384.6 K shares>. The last five (5) sessions (pre Monday) saw a range of $33.94 to $38.55 while June was a good month for appreciation having opened at $35.29; saw a low of $33.72 and a high of $39.94 in twenty-one (21) sessions – SELL;

CRISPR Therapeutics (CRSP +$1.29), Intellia (NTLA +$1.37) and Editas Medicine (EDIT +$1.16) are again getting lofty after feeling pain and are trading magnets – SELL:

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.